1. Giant solitary fibrous tumour of the pleura : case report and review of the literatureAnton Crnjac, Bojan Veingerl, Damjan Vidovič, Rajko Kavalar, Aljaž Hojski, 2015, pregledni znanstveni članek Povzetek: Background. Solitary fibrous tumours of the pleura (SFTP) are rare tumours. They are mostly benign. Only around 12% of them are malignant. In the initial stage they are mostly asymptomatic and by growing they cause chest pain, irritating cough and dyspnoea on account of the pressure created on the surrounding structures. Rare giant tumours have compression symptoms on the mediastinal structures. The condition requires tiered diagnostic radiology. Preoperative biopsy is not successful in most cases. The therapy of choice is radical surgical tumour removal. Malignant or nonradically removed benign solitary fibrous tumours of the pleura additionally require neoadjuvant therapy. Case report. A 68-year old patient was hospitalized for giant solitary fibrous tumour of the pleura in the right pleural cavity. With its expansive growth the tumour caused the shift of the mediastinum by compressing the lower vena cava, right cardiac auricle as well as the intermediate and lower lobe bronchus. Due to cardiac inflow obstruction and right lung collapse, the patient's life was endangered with signs of cardio-respiratory failure. After preoperative diagnostic radiology, the tumour was surgically removed. Postoperatively, the patient's condition improved. No disease recurrence was diagnosed after a year. Conclusions. Giant solitary fibrous tumour of the pleura may cause serious and life-threatening conditions by causing compression of the pleural cavity with its expansive growth. Early diagnosis of the condition enables less aggressive as well as video-assisted thoracic surgery in patients with significantly better state of health. Large tumour surgeries in cardio-respiratory affected patients are highly risk-associated procedures.
Objavljeno v DiRROS: 23.04.2024; Ogledov: 6; Prenosov: 0
 Celotno besedilo (2,16 MB)
Gradivo ima več datotek! Več... |
2. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer : correlation with traditional prognostic factorsMaja Lampelj, Darja Arko, Nina Čas-Sikošek, Rajko Kavalar, Maja Ravnik, Barbara Jezeršek Novaković, Sarah Dobnik, Nina Fokter Dovnik, Iztok Takač, 2015, izvirni znanstveni članek Povzetek: Background. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) play a key role in tumour invasion and metastasis. High levels of both proteolytic enzymes are associated with poor prognosis in breast cancer patients. The purpose of this study was to evaluate the correlation between traditional prognostic factors and uPA and PAI-1 expression in primary tumour of breast cancer patients. Patients and methods. 606 primary breast cancer patients were enrolled in the prospective study in the Department of gynaecological oncology and breast oncology at the University Medical Centre Maribor between the years 2004 and 2010. We evaluated the traditional prognostic factors (age, menopausal status, tumour size, pathohistological type, histologic grade, lymph node status, lymphovascular invasion and hormone receptor status), together with uPA and PAI-1. We used Spearman%s rank correlation, Mann Whitney U test and X2 test for statistical analysis. Results. Our findings indicate a positive correlation between uPA and tumour size (p < 0.001), grade (p < 0.001), histological type (p < 0.001), lymphovascular invasion (p = 0.01) and a negative correlation between uPA and hormone receptor status (p < 0.001). They also indicate a positive correlation between PAI-1 and tumour size (p = 0.004), grade (p < 0.001), pathohistological type (p < 0.001) and negative correlation between PAI-1 and hormone receptor status (p = 0.002). Conclusions. Our study showed a relationship between uPA and PAI-1 and traditional prognostic factors. Their role as prognostic and predictive factors remains to be further evaluated.
Ključne besede: urokinase plasminogen activator, plasminogen activator inhibitor, breast cancer
Objavljeno v DiRROS: 17.04.2024; Ogledov: 79; Prenosov: 39
Celotno besedilo (571,67 KB)
Gradivo ima več datotek! Več... |
3. The influence of cytokine gene polymorphisms on the risk of developing gastric cancer in patients with Helicobacter pylori infectionDavid Štubljar, Samo Jeverica, Tomislav Jukić, Miha Skvarč, Tadeja Pintar, Bojan Tepeš, Rajko Kavalar, Borut Štabuc, Alojz Ihan, 2015, izvirni znanstveni članek Ključne besede: cytokine gene, gastric cancer, Helicobacter pylori infection
Objavljeno v DiRROS: 16.04.2024; Ogledov: 75; Prenosov: 14
Celotno besedilo (587,90 KB) |
4. Potek zdravljenja bolnice s patološkim brisom in negativnim testom HPVTatjana Kodrič, Kristina Gornik-Kramberger, Simona Hutter-Čelik, Helena Gutnik, Rajko Kavalar, Alenka Repše-Fokter, 2013, objavljeni strokovni prispevek na konferenci Povzetek: Presejalni program zgodnjega odkrivanja materničnega vratu temelji v Sloveniji na citološkem pregledu brisov materničnega vratu. V primeru patološkega citološkega izvida je potrebno opraviti tudi dodatne diagnostične preiskave in načrtovati ustrezno zdravljenje. Čeprav je velika večina predrakavih in rakavih bolezenskih sprememb na materničnem vratu pogojena s HPV-okužbo, pa se je potrebno zavedati, da obstoja možnost bolezni redko tudi pri populaciji z negativnim izvidom testa HPV.
Ključne besede: maternični vrat, novotvorbe, brisi, humani papiloma virus, prikaz primera
Objavljeno v DiRROS: 07.04.2020; Ogledov: 1978; Prenosov: 574
Celotno besedilo (161,84 KB) |
5. Potek bolezni pri bolnici s CIN in začetnim karcinomom, ki se ni želela zdravitiUršula Salobir Gajšek, Filip Simoniti, Simona Šramek Zatler, Alenka Repše-Fokter, Rajko Kavalar, Alenka Repše-Fokter, 2013, objavljeni strokovni prispevek na konferenci Ključne besede: maternični vrat, novotvorbe, brisi, odklonitev zdravljenja
Objavljeno v DiRROS: 07.04.2020; Ogledov: 1850; Prenosov: 502
Celotno besedilo (184,51 KB) |
6. Prikaz bolnika z zasevkom v telesu vretenca L1 nejasnega izvoraMarko Hanc, Janez Ravnik, Igor Movrin, Rajko Kavalar, Gregor Rečnik, 2013, strokovni članek Povzetek: Zasevki malignomov v kosti so znatno pogostejši od primarnih novotvorb. Približno 2 % zasevkov, kljub številnim opravljenim preiskavam, ostane brez jasnega mesta izvora. Predstavljeni 59-letni bolnik je bil sprejet zaradi patološkega preloma telesa vretenca L1. Po odstranitvi večine telesa, natančni patološki preiskavi in razširjeni diagnostiki, vprašanje glede izvora primarnega tumorja še vedno ostaja nerazrešeno.
Ključne besede: malignom, zasevki v kosti, diagnostika, zdravljenje
Objavljeno v DiRROS: 31.08.2018; Ogledov: 3013; Prenosov: 764
Celotno besedilo (405,10 KB) |
